← Back to KROS

Keros Therapeutics, Inc. - common stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 03/08/2026Mar 2026Filed 03/08/2026Sep 2025Filed 05/11/2025Jun 2025Filed 03/08/2026Mar 2025Filed 03/08/2026Sep 2024Filed 05/11/2025Jun 2024Filed 05/11/2025Mar 2024Filed 05/11/2025
$0$0.4$14$18$211$0.4$0$0.1
−$29−$24−$7.3−$31$148−$53−$45−$43
−$1.45−$1.21−$0.18−$0.76$3.62−$1.41−$1.25−$1.21
2020414141383636

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.